RU2018116572A - Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA - Google Patents
Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA Download PDFInfo
- Publication number
- RU2018116572A RU2018116572A RU2018116572A RU2018116572A RU2018116572A RU 2018116572 A RU2018116572 A RU 2018116572A RU 2018116572 A RU2018116572 A RU 2018116572A RU 2018116572 A RU2018116572 A RU 2018116572A RU 2018116572 A RU2018116572 A RU 2018116572A
- Authority
- RU
- Russia
- Prior art keywords
- amount
- pharmaceutical composition
- composition according
- epa
- unit dosage
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims 2
- 238000009472 formulation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 46
- 238000000034 method Methods 0.000 claims 30
- 239000002552 dosage form Substances 0.000 claims 21
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 20
- 210000002381 plasma Anatomy 0.000 claims 19
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 18
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 14
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 14
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 14
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 14
- 210000002966 serum Anatomy 0.000 claims 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 10
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 10
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 9
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 9
- 235000021342 arachidonic acid Nutrition 0.000 claims 9
- 229940114079 arachidonic acid Drugs 0.000 claims 9
- 108010010803 Gelatin Proteins 0.000 claims 8
- 229920000159 gelatin Polymers 0.000 claims 8
- 239000008273 gelatin Substances 0.000 claims 8
- 235000019322 gelatine Nutrition 0.000 claims 8
- 235000011852 gelatine desserts Nutrition 0.000 claims 8
- 239000007903 gelatin capsule Substances 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 5
- 239000004202 carbamide Substances 0.000 claims 5
- 150000003626 triacylglycerols Chemical class 0.000 claims 5
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 4
- 241000282898 Sus scrofa Species 0.000 claims 3
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000010668 complexation reaction Methods 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- VCSQUSNNIFZJAP-AAQCHOMXSA-N ethyl (7Z,10Z,13Z,16Z,19Z)-docosapentaenoate Chemical compound CCOC(=O)CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC VCSQUSNNIFZJAP-AAQCHOMXSA-N 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- HTEAGOMAXMOFFS-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C HTEAGOMAXMOFFS-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Developing Agents For Electrophotography (AREA)
- Materials For Photolithography (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261583796P | 2012-01-06 | 2012-01-06 | |
| US61/583,796 | 2012-01-06 | ||
| US201261664047P | 2012-06-25 | 2012-06-25 | |
| US61/664,047 | 2012-06-25 | ||
| US201261669940P | 2012-07-10 | 2012-07-10 | |
| US61/669,940 | 2012-07-10 | ||
| US201261680622P | 2012-08-07 | 2012-08-07 | |
| US61/680,622 | 2012-08-07 | ||
| US201261710517P | 2012-10-05 | 2012-10-05 | |
| US61/710,517 | 2012-10-05 | ||
| US201261713388P | 2012-10-12 | 2012-10-12 | |
| US61/713,388 | 2012-10-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014128500A Division RU2664429C2 (ru) | 2012-01-06 | 2013-01-04 | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018116572A true RU2018116572A (ru) | 2018-10-23 |
Family
ID=48744082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018116572A RU2018116572A (ru) | 2012-01-06 | 2013-01-04 | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA |
| RU2014128500A RU2664429C2 (ru) | 2012-01-06 | 2013-01-04 | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014128500A RU2664429C2 (ru) | 2012-01-06 | 2013-01-04 | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA |
Country Status (35)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| HRP20181418T1 (hr) * | 2012-01-06 | 2018-11-30 | Omthera Pharmaceuticals Inc. | Dpa-obogaćeni pripravci omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline |
| CN104661654A (zh) * | 2012-05-07 | 2015-05-27 | 翁特拉制药公司 | 他汀类药物和ω-3脂肪酸的组合物 |
| CA2916208A1 (en) * | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| GB201216385D0 (en) * | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| CA2889238A1 (en) * | 2012-10-23 | 2014-05-01 | Deakin University | Method for reducing triglycerides |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| US9452151B2 (en) * | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| WO2015011724A2 (en) | 2013-07-22 | 2015-01-29 | Kms Health Center Pvt Ltd | A novel omega -3 fatty acid composition with a plant extract |
| WO2015024055A1 (en) * | 2013-08-20 | 2015-02-26 | Deakin University | Separation of omega-3 fatty acids |
| EP3738586A1 (en) | 2013-10-30 | 2020-11-18 | Patheon Softgels Inc. | Enteric soft capsules comprising polyunsaturated fatty acids |
| JP2016538288A (ja) | 2013-11-15 | 2016-12-08 | ディグニティ サイエンシス リミテッド | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| CA2947741A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| EP3692986A1 (en) | 2014-06-04 | 2020-08-12 | DS Biopharma Limited | Pharmaceutical compositions comprising dgla and use of same |
| EA201692548A1 (ru) | 2014-06-18 | 2017-10-31 | ТЕТИС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Минеральные аминокислотные комплексы активных веществ |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| US9895333B2 (en) | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
| WO2016069446A1 (en) * | 2014-10-28 | 2016-05-06 | Omthera Pharmaceuticals Inc | Methods for modulating plasma levels of lipoproteins |
| WO2016073335A1 (en) * | 2014-11-05 | 2016-05-12 | Omthera Pharmaceuticals Inc. | Methods of treatment |
| US20160192126A1 (en) * | 2014-12-31 | 2016-06-30 | Silver Spring Networks, Inc. | System and method for tracking a device |
| MA41611A (fr) | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
| WO2016178066A1 (en) * | 2015-05-01 | 2016-11-10 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
| HK1250345A1 (zh) | 2015-05-13 | 2018-12-14 | Afimmune Limited | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| CN108025181A (zh) | 2015-07-21 | 2018-05-11 | 艾菲穆恩有限公司 | 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物 |
| KR20180094516A (ko) | 2015-12-18 | 2018-08-23 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
| US10263794B2 (en) * | 2016-05-19 | 2019-04-16 | Linear Technology Corporation | Maintain power signature controller at power interface of PoE or PoDL system |
| JP6906047B2 (ja) | 2016-06-03 | 2021-07-21 | テティス・ファーマシューティカルズ・エルエルシー | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 |
| GB201611920D0 (en) | 2016-07-08 | 2016-08-24 | Astrazeneca Ab | Pharmaceutical compositions |
| IL270676B2 (en) | 2017-05-16 | 2024-11-01 | Ability Pharmaceuticals S L | A pharmaceutical combination comprising a polyunsaturated fatty acid and a chemotherapeutic agent for the treatment of a cancer |
| WO2019008101A1 (en) | 2017-07-06 | 2019-01-10 | Evonik Technochemie Gmbh | ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS |
| CA3072658C (en) | 2017-08-15 | 2023-01-24 | Evonik Operations Gmbh | Tablets with high active ingredient content of omega-3 fatty acid amino acid salts |
| EP3586642A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Ala enriched polyunsaturated fatty acid compositions |
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| AU2020326262B2 (en) | 2019-08-08 | 2025-09-11 | Evonik Operations Gmbh | Down streaming process for the production of polyunsaturated fatty acid salts |
| EP4009961A1 (en) | 2019-08-08 | 2022-06-15 | Evonik Operations GmbH | Solubility enhancement of poorly soluble actives |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5735512A (en) | 1980-06-27 | 1982-02-26 | Nippon Oil & Fats Co Ltd | Preventive and remedy for thrombosis |
| US4377526A (en) | 1981-05-15 | 1983-03-22 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid and its esters |
| BR8803255A (pt) | 1981-11-10 | 1990-02-06 | Century Lab Inc | Processo de extracao e purificacao de acidos graxos poli-insaturados de fontes naturais |
| JPS59157018A (ja) | 1983-02-27 | 1984-09-06 | Furointo Sangyo Kk | 新規なる被覆含油カプセル剤形 |
| JPS59225115A (ja) | 1983-06-06 | 1984-12-18 | Ota Seiyaku Kk | 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル |
| JPS61126016A (ja) | 1984-11-22 | 1986-06-13 | Toagosei Chem Ind Co Ltd | 不飽和脂肪酸を内相物としたマイクロカプセル |
| EP0347509A1 (en) | 1988-06-21 | 1989-12-27 | Century Laboratories Inc. | A process of extraction and purification of polyunsaturated fatty acids from natural sources |
| US5243046A (en) | 1986-12-17 | 1993-09-07 | Nestec S.A. | Process for the continuous fractionation of a mixture of fatty acids |
| CH669208A5 (fr) | 1986-12-17 | 1989-02-28 | Nestle Sa | Procede de fractionnement en continu d'un melange d'acides gras. |
| DE3863678D1 (de) | 1987-04-27 | 1991-08-22 | Efamol Holdings | Lithiumsalze enthaltende pharmazeutische zubereitungen. |
| IT1205043B (it) | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
| ZA885473B (en) | 1987-08-07 | 1989-03-29 | Century Lab Inc | Free fatty acids for treatment of diabetes mellitus |
| US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
| NL9201438A (nl) | 1992-08-11 | 1994-03-01 | Prospa Bv | Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen. |
| AU5995294A (en) | 1993-01-15 | 1994-08-15 | Abbott Laboratories | Structured lipids |
| DE69401506T2 (de) | 1993-04-29 | 1997-09-11 | Norsk Hydro As | Verfahren zur chromatografischer fraktionierung von fettsäuren und ihre derivaten |
| JPH0753356A (ja) | 1993-08-16 | 1995-02-28 | Morishita Jintan Kk | 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法 |
| US5767156A (en) | 1993-10-06 | 1998-06-16 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| IT1264987B1 (it) | 1993-12-14 | 1996-10-17 | Prospa Bv | Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono |
| US5494684A (en) | 1994-02-23 | 1996-02-27 | Bar-Ilan University | Plant protection from infection by Phytophthora infestans using fish oil |
| GB9404483D0 (en) | 1994-03-08 | 1994-04-20 | Norsk Hydro As | Refining marine oil compositions |
| RU2127115C1 (ru) | 1994-03-28 | 1999-03-10 | Владимир Константинович Гаврисюк | Смесь омега-3 полиненасыщенных жирных кислот |
| ES2131129T3 (es) | 1994-05-09 | 1999-07-16 | Nestle Sa | Procedimiento para la preparacion de un concentrado de esteres de acidos grasos poliinsaturados. |
| IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| JPH08100191A (ja) * | 1994-09-30 | 1996-04-16 | Nisshin Flour Milling Co Ltd | 高度不飽和脂肪酸またはそのエステルの精製方法 |
| NL9401743A (nl) | 1994-10-20 | 1996-06-03 | Prospa Bv | Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten. |
| GB9509764D0 (en) | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| GB2300807B (en) | 1995-05-15 | 1999-08-18 | Tillotts Pharma Ag | Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease |
| AU2738497A (en) | 1996-04-24 | 1997-11-12 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
| US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| JPH1095744A (ja) * | 1996-09-20 | 1998-04-14 | Nof Corp | 高度不飽和脂肪酸又はそのアルキルエステルの製造方法 |
| EP0843972B1 (en) * | 1996-11-20 | 2002-07-31 | N.V. Nutricia | Nutritional composition comprising fats for the treatment of the metabolic syndrome |
| GB9701705D0 (en) | 1997-01-28 | 1997-03-19 | Norsk Hydro As | Purifying polyunsatured fatty acid glycerides |
| EP0973934A4 (en) | 1997-02-25 | 2003-02-05 | Genzyme Transgenics Corp | TRANSGEN PRODUCED NON-SECRETED PROTEINS. |
| US6852870B2 (en) | 1999-03-22 | 2005-02-08 | Andrew Stoll | Omega-3 fatty acids in the treatment of depression |
| KR100587551B1 (ko) | 1997-12-10 | 2006-06-08 | 싸이클로스포린 테라퓨틱스 리미티드 | 오메가-3 지방산 오일을 함유하는 약학 조성물 |
| NO312973B1 (no) | 1999-02-17 | 2002-07-22 | Norsk Hydro As | Lipase-katalysert forestring av marine oljer |
| US7112609B2 (en) | 1999-06-01 | 2006-09-26 | Drugtech Corporation | Nutritional supplements |
| JP2001054396A (ja) | 1999-06-08 | 2001-02-27 | Nippon Suisan Kaisha Ltd | リパーゼによる高度不飽和脂肪酸含有油脂の製造方法 |
| WO2001006983A2 (en) | 1999-07-22 | 2001-02-01 | Incell Corporation, Llc | Fatty acids to minimize cancer therapy side effects |
| NO310113B1 (no) | 1999-08-11 | 2001-05-21 | Norsk Hydro As | Fremgangsmåte for utvinning av flerumettede fettsyrer fra ureakomplekser |
| EP1211955A1 (en) | 1999-08-30 | 2002-06-12 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| HK1046851A1 (en) | 1999-08-31 | 2003-01-30 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
| EP1106072B1 (en) | 1999-12-10 | 2005-11-30 | Loders Croklaan B.V. | Palmitoleic acid and its use in foods |
| WO2001049282A2 (en) | 2000-01-06 | 2001-07-12 | Martek Biosciences Corporation | Therapeutic preparations of highly unsaturated fatty acids |
| ATE305810T1 (de) | 2000-05-22 | 2005-10-15 | Pro Aparts Investimentos E Con | Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| GB0016452D0 (en) | 2000-07-04 | 2000-08-23 | Kilgowan Limited | Vitamin K and essential fatty acids |
| EP1178103A1 (en) | 2000-08-02 | 2002-02-06 | Dsm N.V. | Purifying crude pufa oils |
| KR20010008387A (ko) | 2000-11-30 | 2001-02-05 | 이성권 | 결정화방법을 이용한 고순도 불포화지방산의 분리 정제 방법 |
| DK1406641T3 (da) | 2001-06-18 | 2009-05-04 | Neptune Technologies & Bioress | Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme |
| CN1197564C (zh) * | 2001-09-30 | 2005-04-20 | 中国药品生物制品检定所 | 海狗油在制备治疗脂代谢紊乱药物中的应用 |
| ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| GB2385852A (en) | 2002-02-27 | 2003-09-03 | Rothamsted Ex Station | Delta 6-desaturases from Primulaceae |
| AU2003218319A1 (en) | 2002-03-22 | 2003-10-13 | Doc's Guide, Inc. | Multivitamin and mineral nutritional supplement |
| DE10214005A1 (de) | 2002-03-27 | 2003-10-09 | Volker Bartz | Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente |
| ITMI20020731A1 (it) | 2002-04-08 | 2003-10-08 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3 |
| NZ518504A (en) | 2002-04-22 | 2005-05-27 | Ind Res Ltd | Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions |
| EP2295529B2 (en) | 2002-07-11 | 2022-05-18 | Basf As | Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use |
| SE0202188D0 (sv) | 2002-07-11 | 2002-07-11 | Pronova Biocare As | A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| NO319194B1 (no) | 2002-11-14 | 2005-06-27 | Pronova Biocare As | Lipase-katalysert forestringsfremgangsmate av marine oljer |
| US8017651B2 (en) | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
| WO2004056370A1 (en) | 2002-12-20 | 2004-07-08 | Pronova Biocare As | Use of a fatty acid composition for treatment of male infertility |
| US20070104856A1 (en) | 2003-05-05 | 2007-05-10 | Hakon Standal | Fish oils with an altered fatty acid profile, method of producing same and their use |
| US6846942B2 (en) | 2003-05-20 | 2005-01-25 | David Rubin | Method for preparing pure EPA and pure DHA |
| JP3884465B2 (ja) | 2003-07-09 | 2007-02-21 | 株式会社Ｊ−オイルミルズ | 長鎖高度不飽和脂肪酸を含む抗酸化油脂組成物 |
| US7759507B2 (en) | 2003-09-05 | 2010-07-20 | Abbott Laboratories | Lipid system and methods of use |
| ITMI20032247A1 (it) | 2003-11-19 | 2005-05-20 | Tiberio Bruzzese | Interazione di derivati polari di composti insaturi con substrati inorganici |
| SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
| GB0413730D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| GB0413729D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| US20070265341A1 (en) | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
| US20080193549A1 (en) | 2004-07-05 | 2008-08-14 | Otago Innovation Limited | Hoki Fish Liver Oil, Fractions Thereof And Therapeutic Uses |
| RU2388490C2 (ru) | 2004-07-19 | 2010-05-10 | Тиа Медика Ас | Композиция, содержащая растительный или рыбий жир, и соединения, содержащие неокисляющиеся структурные элементы жирных кислот |
| ES2660700T3 (es) | 2004-07-19 | 2018-03-23 | Bergen Teknologioverføring As | Composición que comprende aceites vegetales y/o de pescado y entidades de ácidos grasos no oxidables |
| WO2007130714A1 (en) | 2006-02-01 | 2007-11-15 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
| NZ552389A (en) | 2004-08-06 | 2009-05-31 | Transform Pharmaceuticals Inc | Statin pharmaceutical compositions and related methods of treatment |
| WO2007130713A1 (en) | 2006-02-01 | 2007-11-15 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
| WO2006017692A2 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
| JP2008512490A (ja) | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス，インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
| US8001922B2 (en) | 2004-09-28 | 2011-08-23 | Atrium Medical Corporation | Application of a coating on a medical device |
| US20070191467A1 (en) * | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
| DE102004062141A1 (de) | 2004-12-23 | 2006-07-06 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Verfahren zur Herstellung eines Rohöls aus Gemischen von Mikroorganismen und Pflanzen, das so hergestellte Öl sowie die spezifischen Verwendungen des so hergestellten und gegebenenfalls zusätzlich raffinierten Öls |
| CA2594781A1 (en) | 2005-01-24 | 2006-07-27 | Pronova Biocare As | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases |
| US20080279935A1 (en) | 2005-02-18 | 2008-11-13 | Swg Invest As | Composition Comprising a Powder Containing Microencapsulated Polyunsaturated Long-Chain Esterified Fatty Acids Distributed in an Effervescent Base |
| WO2006096806A2 (en) | 2005-03-08 | 2006-09-14 | Reliant Pharmaceutiacals, Inc. | Treatment with statin and omega-3 fatty acids and a combination product thereof |
| DE102005013779A1 (de) | 2005-03-22 | 2006-09-28 | Basf Plant Science Gmbh | Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen |
| WO2006102896A2 (en) | 2005-03-29 | 2006-10-05 | Aalborg Universitet | A process to concentrate ω3-pufa from fish oil by selective hydrolysis using cutinase immobilized on zeolite nay |
| KR100539357B1 (ko) | 2005-04-11 | 2005-12-28 | 동부한농화학 주식회사 | 불포화 지방산의 제조방법 |
| CN102050720B (zh) | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
| US7485323B2 (en) | 2005-05-31 | 2009-02-03 | Gelita Ag | Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions |
| EP1903883A4 (en) | 2005-07-01 | 2010-06-23 | Martek Biosciences Corp | OIL PRODUCT CONTAINING MULTIPLE UNSATURATED FATTY ACIDS AND ITS USES AND MANUFACTURING |
| US20070020340A1 (en) | 2005-07-25 | 2007-01-25 | David Rubin | Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension |
| BRPI0614378A2 (pt) | 2005-08-04 | 2011-03-22 | Transform Pharmaceuticals Inc | formulações compreendendo fenofibrato e uma estatina, e métodos de tratamento relacionados |
| ITMI20051560A1 (it) | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
| US20070134493A1 (en) | 2005-12-08 | 2007-06-14 | Kanji Meghpara | Compositions and capsules with stable hydrophilic layers |
| MX286464B (es) | 2005-12-20 | 2011-05-10 | Cenestra Llc | Formulaciones de acido graso omega 3. |
| FR2896172B1 (fr) | 2006-01-17 | 2008-10-10 | Polaris Soc Par Actions Simpli | Nouveau procede de stabilisation des acides gras polyinsatures et les compositions ainsi obtenus. |
| DE102006008030A1 (de) | 2006-02-21 | 2007-08-23 | Basf Plant Science Gmbh | Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren |
| AR059376A1 (es) | 2006-02-21 | 2008-03-26 | Basf Plant Science Gmbh | Procedimiento para la produccion de acidos grasos poliinsaturados |
| WO2007128801A1 (en) | 2006-05-08 | 2007-11-15 | Novartis Ag | Combination of organic compounds |
| US8003813B2 (en) | 2006-06-27 | 2011-08-23 | Pos Pilot Plant Corporation | Process for separating saturated and unsaturated fatty acids |
| KR100684641B1 (ko) | 2006-07-25 | 2007-02-22 | 주식회사 일신웰스 | 유지 조성물, 이를 함유하는 식품 및 건강보조식품 |
| US20090304784A1 (en) | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
| KR100758664B1 (ko) | 2006-08-16 | 2007-09-13 | (주)케비젠 | 불포화지방산 함유 마이크로캡슐의 제조방법, 이 방법에의해 제조된 마이크로캡슐 및 이를 포함하는 제품 |
| CN101194913A (zh) * | 2006-12-05 | 2008-06-11 | 张金生 | 治疗血脂偏高的天然海豹油浓缩生物制剂及其制备工艺 |
| NZ578872A (en) | 2007-01-10 | 2012-07-27 | Ocean Nutrition Canada Ltd | Vegetarian microcapsules |
| JP2010515773A (ja) | 2007-01-16 | 2010-05-13 | リライアント・ファーマシューティカルズ・インコーポレイテッド | 非ステロイド系抗炎症薬およびオメガ−３脂肪酸を用いる治療ならびにその組合せ生成物 |
| EP2120920A4 (en) | 2007-02-20 | 2011-06-15 | Martek Biosciences Corp | OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE |
| AU2008229604B2 (en) | 2007-03-20 | 2013-05-30 | Scf Pharma Inc. | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| CA2685272A1 (en) | 2007-04-26 | 2008-11-06 | Patrick Adlercreutz | A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof |
| CA2692394A1 (en) | 2007-07-06 | 2009-01-15 | Seth J. Baum | Fatty acid compositions and methods of use |
| CL2008002020A1 (es) | 2007-07-12 | 2008-11-14 | Ocean Nutrition Canada Ltd | Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite. |
| WO2009014452A1 (en) | 2007-07-25 | 2009-01-29 | Epax As | Omega-3 fatty acid fortified composition |
| CA2693070A1 (en) | 2007-07-30 | 2009-02-05 | Nippon Suisan Kaisha, Ltd. | Method for producing epa-enriched oil and dha-enriched oil |
| WO2009020406A1 (en) | 2007-08-07 | 2009-02-12 | Granate Seed Limited | Methods of making lipid substances, lipid substances made thereby and uses thereof |
| WO2009028457A1 (ja) | 2007-08-29 | 2009-03-05 | Shinshu University | 非アルコール性脂肪肝炎治療薬 |
| DE102007055344A1 (de) | 2007-11-19 | 2009-05-20 | K. D. Pharma Bexbach Gmbh | Neue Verwendung von Omega-3-Fettsäure(n) |
| CN101969932A (zh) | 2008-01-10 | 2011-02-09 | 武田药品工业株式会社 | 胶囊制剂 |
| US20090182049A1 (en) | 2008-01-16 | 2009-07-16 | Joar Arild Opheim | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
| KR20110021886A (ko) | 2008-05-15 | 2011-03-04 | 프로노바 바이오파마 노르지 에이에스 | 크릴 오일 처리 방법 |
| ES2862336T3 (es) | 2008-09-02 | 2021-10-07 | Amarin Pharmaceuticals Ie Ltd | Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma |
| US20100062057A1 (en) | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
| CA2739440C (en) | 2008-10-02 | 2018-11-06 | Feyecon B.V. | Microalgae extract containing .omega.3-polyunsaturated fatty acids and method for extracting oil from micro-organisms |
| PT2349250T (pt) | 2008-10-31 | 2017-07-25 | Lipid Pharmaceuticals Ehf | Ácidos gordos para uso como um medicamento |
| SI2596786T1 (sl) | 2009-02-10 | 2020-03-31 | Amarin Pharmaceuticals Ireland Limited, | Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
| CN101822651A (zh) * | 2009-03-05 | 2010-09-08 | Dpa工业公司 | 可咀嚼胶囊及其制备方法 |
| WO2010103402A1 (en) | 2009-03-09 | 2010-09-16 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof |
| JP5872453B2 (ja) | 2009-04-17 | 2016-03-01 | ナタク ファルマ エセ．エレ． | フィタン酸含量が低く、ω−３脂肪酸に富む組成物 |
| US20120093922A1 (en) | 2009-04-29 | 2012-04-19 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| KR101343249B1 (ko) | 2009-04-29 | 2013-12-19 | 아마린 파마, 인크. | 안정한 제약 조성물 및 그의 사용 방법 |
| EP3067056A1 (en) | 2009-05-01 | 2016-09-14 | UAS Laboratories LLC | Bacterial compositions for prophylaxis and treatment of degenerative disease |
| KR102012111B1 (ko) | 2009-06-15 | 2019-08-19 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
| WO2011028689A1 (en) | 2009-09-01 | 2011-03-10 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
| KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
| KR102354949B1 (ko) | 2009-10-23 | 2022-01-24 | 바스프 에이에스 | 지방산 오일 혼합물의 코팅된 캡슐 및 정제 |
| RU2009145010A (ru) | 2009-12-04 | 2011-06-20 | Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU) | Композиция омега-3 и омега-6 полиненасыщенных жирных кислот |
| WO2011095284A1 (de) | 2010-02-02 | 2011-08-11 | Cognis Ip Management Gmbh | Anreicherung von mehrfach ungesättigten fettsäuren |
| GB201006204D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| WO2011133610A1 (en) | 2010-04-22 | 2011-10-27 | E. I. Du Pont De Nemours And Company | Method for obtaining polyunsaturated fatty acid-containing compositions from microbial biomass |
| US9476008B2 (en) | 2010-06-25 | 2016-10-25 | Epax As | Process for separating polyunsaturated fatty acids from long chain unsaturated or less saturated fatty acids |
| JP2013537185A (ja) | 2010-09-08 | 2013-09-30 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 遊離酸の形のｅｐａおよびｄｈａを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物 |
| PE20140202A1 (es) | 2010-09-24 | 2014-03-15 | Pronova Biopharma Norge As | Proceso para concentrar acidos grasos omega-3 |
| WO2012083034A1 (en) | 2010-12-15 | 2012-06-21 | Louis Sanfilippo | Modulation of neurotrophic factors by omega-3 fatty acid formulations |
| WO2012087153A1 (en) | 2010-12-23 | 2012-06-28 | Marine Bioproducts As | Enrichment of marine oils with omega-3 polyunsaturated fatty acids by lipase-catalysed hydrolysis |
| EP2476425B1 (en) | 2011-01-14 | 2014-03-19 | Visiotact Pharma | Composition comprising OPC and Omega-3 for preventing and/or inhibiting the development of diabetic retinopathy |
| CA2827561A1 (en) | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd) |
| CA2827579A1 (en) * | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease |
| EP2675444A1 (en) | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics |
| EP2675442A1 (en) | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events |
| CA2827585A1 (en) | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases |
| WO2012112902A1 (en) | 2011-02-18 | 2012-08-23 | Martek Biosciences Corporation | Methods of preparing free polyunsaturated fatty acids |
| US20140051877A1 (en) | 2011-04-28 | 2014-02-20 | Nandakishore Jeevanrao Duragkar | Eicosapentaenoic acid (epa) as polyunsaturated free fatty acid in its directly compressible powder form and process of isolation thereof |
| CN102311868B (zh) | 2011-04-29 | 2017-05-24 | 塞拉斯有限责任公司 | 一种无溶剂提取富含磷脂和中性油脂的磷虾油的方法 |
| US8697676B2 (en) | 2011-06-15 | 2014-04-15 | Ronald E Rosedale | Omega-3 fatty acid nutriceutical composition and optimization method |
| JP2014531444A (ja) * | 2011-09-15 | 2014-11-27 | オムセラ・ファーマシューティカルズ・インコーポレイテッド | 抗血小板療法に対する耐性を治療するか、逆転させるか、阻害するかまたは防止するための方法および組成物 |
| US20140316003A1 (en) | 2011-10-21 | 2014-10-23 | Omthera Pharmaceuticals, Inc. | Methods and compositions for treating or preventing attention deficit hyperactivity disorder |
| US9861605B2 (en) | 2011-10-24 | 2018-01-09 | Stable Solutions Llc | Enriched injectable emulsion containing selected fatty acid triglycerides |
| HRP20181418T1 (hr) | 2012-01-06 | 2018-11-30 | Omthera Pharmaceuticals Inc. | Dpa-obogaćeni pripravci omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline |
| AU2013240427B2 (en) | 2012-03-30 | 2017-08-03 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
| CN104661654A (zh) | 2012-05-07 | 2015-05-27 | 翁特拉制药公司 | 他汀类药物和ω-3脂肪酸的组合物 |
| US20140194512A1 (en) | 2012-06-17 | 2014-07-10 | Matinas Biopharma, Inc. | Compositions comprising docosapentaenoic acid and methods of use |
| CA2916208A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| GB201216385D0 (en) * | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| WO2016069446A1 (en) | 2014-10-28 | 2016-05-06 | Omthera Pharmaceuticals Inc | Methods for modulating plasma levels of lipoproteins |
| WO2016073335A1 (en) | 2014-11-05 | 2016-05-12 | Omthera Pharmaceuticals Inc. | Methods of treatment |
| WO2016130417A1 (en) | 2015-02-11 | 2016-08-18 | Omthera Pharmaceuticals Inc | Omega-3 fatty acid prodrug compounds and uses thereof |
| MA41611A (fr) | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
-
2013
- 2013-01-04 HR HRP20181418TT patent/HRP20181418T1/hr unknown
- 2013-01-04 EP EP13733671.5A patent/EP2800563B1/en active Active
- 2013-01-04 DK DK13733671.5T patent/DK2800563T3/en active
- 2013-01-04 CN CN201810809253.1A patent/CN108524483A/zh active Pending
- 2013-01-04 CN CN201380012754.2A patent/CN104321055A/zh active Pending
- 2013-01-04 RU RU2018116572A patent/RU2018116572A/ru not_active Application Discontinuation
- 2013-01-04 RS RS20181033A patent/RS57777B1/sr unknown
- 2013-01-04 BR BR112014016788A patent/BR112014016788A8/pt not_active IP Right Cessation
- 2013-01-04 KR KR1020197029482A patent/KR102153245B1/ko not_active Expired - Fee Related
- 2013-01-04 US US13/734,846 patent/US9050308B2/en not_active Expired - Fee Related
- 2013-01-04 MX MX2014008309A patent/MX358319B/es active IP Right Grant
- 2013-01-04 JP JP2014551376A patent/JP6399655B2/ja not_active Expired - Fee Related
- 2013-01-04 RU RU2014128500A patent/RU2664429C2/ru active
- 2013-01-04 CA CA2860512A patent/CA2860512C/en not_active Expired - Fee Related
- 2013-01-04 KR KR1020147021557A patent/KR102153143B1/ko not_active Expired - Fee Related
- 2013-01-04 CN CN201611034149.7A patent/CN107050457A/zh active Pending
- 2013-01-04 WO PCT/US2013/020398 patent/WO2013103902A1/en not_active Ceased
- 2013-01-04 UA UAA201407804A patent/UA114615C2/uk unknown
- 2013-01-04 ES ES13733671.5T patent/ES2685703T3/es active Active
- 2013-01-04 PL PL13733671T patent/PL2800563T3/pl unknown
- 2013-01-04 SG SG11201403805WA patent/SG11201403805WA/en unknown
- 2013-01-04 SG SG10201701004RA patent/SG10201701004RA/en unknown
- 2013-01-04 SI SI201331151T patent/SI2800563T1/sl unknown
- 2013-01-04 EP EP18158463.2A patent/EP3348262A1/en not_active Withdrawn
- 2013-01-04 PT PT13733671T patent/PT2800563T/pt unknown
- 2013-01-04 IN IN6125DEN2014 patent/IN2014DN06125A/en unknown
- 2013-01-04 LT LTEP13733671.5T patent/LT2800563T/lt unknown
- 2013-01-04 US US14/370,730 patent/US20150004224A1/en not_active Abandoned
- 2013-01-04 NZ NZ626699A patent/NZ626699A/en not_active IP Right Cessation
- 2013-01-04 SM SM20180519T patent/SMT201800519T1/it unknown
- 2013-01-04 MY MYPI2014002018A patent/MY165048A/en unknown
- 2013-01-04 HU HUE13733671A patent/HUE039659T2/hu unknown
- 2013-01-04 PE PE2014001081A patent/PE20142459A1/es active IP Right Grant
- 2013-03-12 US US13/797,557 patent/US9050309B2/en not_active Expired - Fee Related
-
2014
- 2014-07-03 IL IL233517A patent/IL233517A/en active IP Right Grant
- 2014-07-04 PH PH12014501553A patent/PH12014501553B1/en unknown
- 2014-07-07 CL CL2014001803A patent/CL2014001803A1/es unknown
- 2014-07-07 DO DO2014000159A patent/DOP2014000159A/es unknown
- 2014-08-05 CO CO14170543A patent/CO7061070A2/es unknown
- 2014-08-05 EC ECIEPI201412527A patent/ECSP14012527A/es unknown
- 2014-08-05 ZA ZA2014/05765A patent/ZA201405765B/en unknown
-
2015
- 2015-03-17 HK HK18110835.8A patent/HK1251457A1/en unknown
- 2015-04-29 US US14/699,556 patent/US10117844B2/en not_active Expired - Fee Related
- 2015-10-06 PH PH12015502307A patent/PH12015502307B1/en unknown
-
2017
- 2017-05-03 IL IL252084A patent/IL252084B/en active IP Right Grant
- 2017-06-23 JP JP2017123521A patent/JP6626857B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-06 CY CY181100930T patent/CY1120663T1/el unknown
- 2018-10-03 US US16/150,363 patent/US20190029985A1/en not_active Abandoned
-
2019
- 2019-04-24 IL IL266231A patent/IL266231B/en not_active IP Right Cessation
- 2019-11-29 JP JP2019217081A patent/JP2020045358A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018116572A (ru) | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA | |
| JP2015503590A5 (enExample) | ||
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| RU2014146111A (ru) | Композиции статинов и омега-3 жирных кислот | |
| KR101383006B1 (ko) | 고중성지방혈증 치료 방법 | |
| RU2020123679A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| NZ627238A (en) | Stable pharmaceutical composition comprising ethyl eicosapentaenoate | |
| US20100130608A1 (en) | Compositions and methods for reducing triglyceride levels | |
| JP2020128412A5 (enExample) | ||
| JP2019048843A5 (enExample) | ||
| RU2017121277A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| WO2011097273A1 (en) | Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine | |
| AU2010326054B2 (en) | Substances for reducing occurrence of major cardiac events comprising red yeast rice and omega-3 polyunsaturated fatty acid or derivative thereof | |
| US20130137767A1 (en) | Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid | |
| CN104147116A (zh) | 一种ω-3鱼油软胶囊 | |
| US20070032546A1 (en) | Novel formulations comprising fenofibrate and a statin, and related methods of treatment | |
| JP6073352B2 (ja) | 安定性が向上したω−３脂肪酸およびＨＭＧ−ＣＯＡ還元酵素阻害剤を含む経口複合製剤 | |
| CN103054845A (zh) | 血脂异常的防治 | |
| KR101830977B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
| CN110139645A (zh) | 用于预防和/或治疗恶病质的ω-3脂肪酸组合物 | |
| CA2504280A1 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| RU2019139669A (ru) | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ | |
| JPH05148140A (ja) | マラリア治療薬 | |
| WO2013138411A1 (en) | Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract | |
| KR20130003501A (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160111 |